SecBot SecBot

AURX

Nuo Therapeutics, Inc.
OTC· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001091596 Biotech & Drug Discovery
$1.30 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $1.30
Median target
$3.00
+131% · range $3.00–3.00
Next earnings
Oct 28
in 1 day
1 year
−44.2%
from $2.33 · Oct 27
30 days
−1.5%
from $1.32
52-week range
$0.7700–2.57
−50% from high · low Aug 14
Avg volume 20D
7.3K
Oct 19 spike 69.8K
Short interest
🔒 Subscribers only
Insider net
+$9.5K
1 buyer · 0 sellers · 12 mo
Filing reports
3
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Oct 28, 2026
Strongest NEUTRAL Nuo Therapeutics closed the $325,000 Second Funding tranche under its existing Loan Agreement on October 6…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • A Dec 16 Roth Capital initiates
  • R May 14 Nuo Therapeutics reported Q1 2026 total revenue of $1.3M, up 169% Yo…
  • X Jul 31 Short interest jumps 1961.3% to 1.5K
  • X Aug 14 Short interest falls 32.3% to 1.0K
  • B Aug 27 to Aug 28 2 days of insider buys: $9.5K by 1 insider, avg $1.09
  • X Aug 31 Short interest jumps 204.5% to 3.2K
  • X Sep 15 Short interest jumps 61.8% to 5.2K
  • X Sep 30 Short interest falls 89.3% to 551

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $9.5K at an average $1.09. No open-market sales. Price is 20% above their cost.

  • TrendUPTREND

    7% above its 50-day average.

The Street

last action Dec 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +131%.Targets as of May 3, 2026.

Recent actions
DateFirmActionRating
Dec 16, 2025Roth Capital
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Oct 28, 2026
Earnings date
AURX Q3 2026 Earnings Scheduled — 2026-10-28
Recent
Jul 29, 2026
Earnings date
AURX Q2 2026 Earnings Scheduled — 2026-07-29
Mar 30, 2026
Earnings date
AURX Q4 2025 Earnings Scheduled — 2026-03-30

Insider ledger

Form 4
$9.5K
bought · 1 insider
$0
sold · 0 insiders
+19.6%
vs their $1.09 cost
DateInsiderTypeValue
Oct 6, 2026
Pittman Scott M.
Director
AWARD$687.00
Oct 6, 2026
Pittman Scott M.
Director
AWARD$6.8K
Aug 28, 2026
JORDEN DAVID EMERSON
CEO/CFO
AWARD$8.7K
Aug 28, 2026
JORDEN DAVID EMERSON
CEO/CFO
BUY$8.7K
Aug 27, 2026
JORDEN DAVID EMERSON
CEO/CFO
AWARD$844.23
Aug 27, 2026
JORDEN DAVID EMERSON
CEO/CFO
BUY$844.23
Jun 30, 2026
WINZER C ERIC
Director
EXERCISE$40.0K
Jun 30, 2026
WINZER C ERIC
Director
TAX W/H$40.0K

Earnings setup

Estimates
Oct 28
reports in 1 day
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 6, 2026 SEC
Nuo Therapeutics closed the $325,000 Second Funding tranche under its existing Loan Agreement on October 6, 2026…
8-K — Impact 3/10
Oct 6, 2026 Insider
Pittman Scott M. was granted 458 shares
Director @ $1.50 ($687.00)
Oct 6, 2026 Insider
Pittman Scott M. was granted 4,500 shares
Director @ $1.50 ($6.8K)
Aug 28, 2026 Insider
JORDEN DAVID EMERSON was granted 7,984 shares
CEO/CFO @ $1.09 ($8.7K)
Aug 17, 2026 SEC
Nuo Therapeutics reported Q2 2026 revenue of ~$1.77M, up >150% YoY, and a net operating loss of ~$167K, improved by…
8-K — Impact 5/10
Jul 29, 2026 Earnings calendar
AURX Q2 2026 Earnings Scheduled — 2026-07-29
May 14, 2026 SEC
Nuo Therapeutics reported Q1 2026 total revenue of $1.3M, up 169% YoY from $484K, driven by Aurix product sales growth…
8-K — Impact 6/10

SecBot reports

3 filings · 2 bullish · 0 bearish · 1 neutral
All AURX filing & press-release reports (3)